Author of

• 12812

  +

  P3.20 - Poster Session 3 - Early Detection and Screening (ID 174)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Imaging, Staging & Screening
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12816

    +

    P3.20-004 - Analysis of exhaled breath for screening of lung cancer patients (ID 1752)

    09:30 - 09:30  |  Author(s): Y. Horio
    • Abstract

    Background
    Lung cancer is a leading cause of cancer death. The lack of symptoms in this disease and problems associated with screening programs for early detection means that patients present late with advanced disease. Studies using low-dose computed tomography proved to be beneficial, and the efficacy of computed tomography scanning as a screening tool for lung cancer is an important and contested topic. However, it has been reported that the increased incidence of cancer after computed tomography scan exposure was mostly due to irradiation. So, computed tomography scans should be limited to situations where there is a definite clinical indication. The search for non-invasive diagnostic methods of lung cancer has led to new avenues of research, including the exploration of the exhaled breath. Previous studies have shown that lung cancer can, in principle, be detected through exhaled-breath analysis. This study evaluated the potential of exhaled-breath analysis for the detection of lung cancer.

    Methods
    Breath samples were taken from patients with lung cancer and from healthy volunteers. The exhaled breath was collected in 1L Analytic- Barrier[TM] bag (OMI ODOR-AIR SERVICE Co. Ltd.). Profiles of volatile organic compounds were determined by gas chromatography/mass spectrometry (Shimadzu Co. Ltd.).

    Results
    We collected breath samples from 111 patients with lung cancer and 29 healthy volunteers using Analytic-Barrier[TM] bags. The volatile organic compounds were extracted with solid phase micro-extraction and analyzed by gas chromatography/mass spectrometry. The number of volatile organic compounds detected in breath samples was 68. Among the volatile organic compounds 10 compounds were found in only breath of the lung cancer patients. In addition, 11 compounds were found at significantly higher concentrations in breath of the lung cancer patients compared to the controls.

    Conclusion
    Our data suggest that compounds in breath could possibly be taken as useful breath biomarkers for discerning potential lung cancer patients and volatile organic compounds analysis could be used as a complementary test for the diagnosis of lung cancer. The vision of exhaled breath analysis is that of a broad use in clinical routine for personalized screening, diagnosis and treatment monitoring.